RUBY Key Statistics, Chart & Performance
The current stock price of RUBY is 0.083 USD. In the past month the price decreased by -70.19%. In the past year, price decreased by -98.34%.
RUBY Latest News, Press Relases and Analysis
RUBY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About RUBY
Company Profile
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company is headquartered in Foxboro, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2018-07-18. The firm is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. The company develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its RTX-321 is an allogeneic artificial antigen presenting cell (aAPC) product candidate, which is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.
Company Info
RUBIUS THERAPEUTICS INC
C/O Verdolino & Lowey, P.C., 124 Washington Street, Suite 101
FOXBORO MASSACHUSETTS 02139 US
CEO: Pablo J. Cagnoni
Employees: 9
Phone: 16176799600.0
RUBIUS THERAPEUTICS INC / RUBY FAQ
What does RUBIUS THERAPEUTICS INC do?
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company is headquartered in Foxboro, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2018-07-18. The firm is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. The company develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its RTX-321 is an allogeneic artificial antigen presenting cell (aAPC) product candidate, which is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.
What is the current price of RUBY stock?
The current stock price of RUBY is 0.083 USD. The price decreased by -33.55% in the last trading session.
Does RUBIUS THERAPEUTICS INC pay dividends?
RUBY does not pay a dividend.
What is the ChartMill rating of RUBIUS THERAPEUTICS INC stock?
RUBY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about RUBIUS THERAPEUTICS INC (RUBY) stock?
7 analysts have analysed RUBY and the average price target is 1.02 USD. This implies a price increase of 1128.92% is expected in the next year compared to the current price of 0.083.
When is the next dividend date for RUBIUS THERAPEUTICS INC (RUBY)?
The next ex-dividend date for RUBIUS THERAPEUTICS INC (RUBY) is February 18, 2022.
What is the next earnings date for RUBY stock?
RUBIUS THERAPEUTICS INC (RUBY) will report earnings on 2023-05-08.
RUBY Technical Analysis
RUBY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RUBY. RUBY has a bad profitability rating. Also its financial health evaluation is rather negative.
RUBY Financial Highlights
Over the last trailing twelve months RUBY reported a non-GAAP Earnings per Share(EPS) of -1.99. The EPS increased by 10.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RUBY Forecast & Estimates
7 analysts have analysed RUBY and the average price target is 1.02 USD. This implies a price increase of 1128.92% is expected in the next year compared to the current price of 0.083.